Speaker: Faye Feller, MD, Executive Vice President, Chief Medical Officer, Geron Pharmaceuticals
Hosted by Aaron Viny, MD, Assistant Professor of Medicine at CUIMC.
Title: "Imetelstat: Telomerase Inhibition in Hematologic Malignancies”
Description: Dr. Feller will review the history of the development of imetelstat, a first in class telomerase inhibitor that was recently approved for the treatment of lower risk myelodysplastic syndrome (MDS). This will include the relevance of telomerase as a target for cancer treatment, with a focus on the preclinical and clinical data that supports treatment of MDS, myelofibrosis and other myeloid malignancies with a telomerase inhibitor, specifically imetelstat.
This event is sponsored by the Herbert Irving Comprehensive Cancer Center's (HICCC) Edward P. Evans Center for Myelodysplastic Syndromes (MDS) at Columbia University, established to foster an all-encompassing approach in studying MDS giving us molecular, cellular genetic and epigenetic insights to develop and test innovative therapies.
